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Abstract
Endometrial cancer remains the most common gynecologic malignancy in the Unites
States and Western Europe. It has been estimated that in 2014, about 52, 630 new cases
of endometrial cancer was diagnosed and about 8,590 died from the disease. Prior to
1988, endometrial cancer was staged clinically. Since that time surgical staging has
been adopted. With the advancement in technology, the vast majority of cases are
being staged and treated surgically via minimally invasive approaches. Conventional
laparoscopy has been a major advancement in staging and treatment of uterine
cancers. However, technical challenges such as 2–D imaging, rigid instruments, and
lack of precision and surgeon fatigue did not translate into widespread adoption of
this technique. With the advent of computer–enhanced robotic telesurgery, this has
dramatically changed the surgical management and staging of endometrial cancer.
Keywords: Endometrial cancer, robotic surgery, oncology, surgical techniques, out‐
comes
1. Introduction
Endometrial cancer is a general definition that often includes all cancers that develop in the
uterus, the most common being endometrioid cancer, or cancers arising in the lining of the
uterus or endometrium.[1-3] In the United States, endometrial cancer is the fourth most
common cancer among women and also the most common gynecological cancer, with on
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average about 6% of all female cancers.[4] In the United States, the number of new cases
estimated to be diagnosed in 2015 is about 55,000 based on data from the American Cancer
Society. Of note, the number of deaths based on these data is expected to be roughly 10,000,
with death rates rising between 0.8% and 1.9% per year within the last 5 years.[2] However,
there is quite a notable variation in worldwide incidence. For example, the highest incidence
is observed in Western Europe, United States, and Canada, while in comparison, Africa and
Asia are shown to have the lowest rates of incidence.[5] The overall increase in the incidence
of this disease during the last decades is mainly related to higher life expectancy within the
developed world.[5]
Endometrial cancer is often described as principally a menopausal state disease, since the
majority of the cases occur in advanced age.[4, 5, 6, 8] The risk of endometrial cancer increases
with the age of the woman. The median age of diagnosis is around 61 years, with the peak
incidence happening between 55 and 70 years old. Data from the research community show
that most cases, about 95%, occur in patients over 40 years of age with only up to 5% of disease
development occurring in women younger than 40.[9-11] Interestingly, the median age of
death is around 73 years.[11] The majority of cases are postulated to be of a sporadic etiology,
although there is a minority with evidence of a hereditary basis. A number of research articles
have been published detailing the correlation of increased risk of endometrial cancer occur‐
rence in women from families with the autosomal dominant hereditary non-polyposis
colorectal cancer (HNPCC) gene. Importantly, endometrial carcinoma is the most common
extra-colonic cancer seen in this condition referred to as Lynch syndrome.[6, 12] The lifetime
risk in these women is about 40% to 60%, and they have a risk of about 40% of developing
endometrial cancer by 70 years old.[6, 11, 13]
A unifying theme among the risk factors is that of increased estrogen exposure.[92] The gradual
growth in incidence especially within the last decade also has some correlation with dietary
and hormonal factors.[14] Obesity, along with increased abdominal girth, is a known risk
factor.[2, 15, 72-73] There has been a notable worldwide increased prevalence of obesity. It
appears from some data that developed countries are more disproportionately affected by this
phenomenon. Increased body mass index (BMI) is also suggested to result in a higher all–cause
mortality and endometrial cancer–specific mortality in endometrial cancer survivors.[16-17]
By contrast, Park et al looked at the relation of pre-treatment BMI on known prognostic factors,
the impact of disease–free survival, and the cause–specific survival in a recent Korean study
of women with endometrial cancer. The study population results, however, found that BMI
was not a significant factor for both disease-free and cause-specific survival.[18] Of note,
endometrial cancer is the third most common gynecological cancer in Korea. A Swedish cohort
study of 11659 women evaluated various lifestyle factors including diet and physical activity
and possible association of risk of endometrial cancer. Overall, 133 cases of endometrial cancer
were observed. The data suggested that an increased risk was noted with very low intake of
fruits and vegetables and statistically significant decreased risk (p < 0.01) with increased
physical activity.[19] Increased weight in early adult life as well as middle age also increased
the risk. The management of peri– and postmenopausal symptoms by unopposed exogenous
estrogen is yet another risk factor.[20-21]
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Risk factors often associated with decreased risk of endometrial cancer are those that help to
decrease the amount of circulating estrogen. These include oral contraceptive (OCP) use, intra-
uterine device (IUD) use, and cigarette smoking. OCPs have been shown to lower the risk by
up to 40%, with protection still noted up to 15 years after last use. A proportional correlation
is seen with protection and length of use.
Although the exact etiology still remains elusive, it is known that most cases arise from atypical
hyperplasia of the lining of the uterus.[72-76] Epithelial cancers of the uterus are generally
divided into two groups. Type I endometrial cancers make up 75% – 90% of endometrial
cancers and are usually low grade, diagnosed in early stages with good prognosis and of
endometrioid histology. They are estrogen–dependent and tend to develop in an environment
of hyperplasia or unopposed estrogen exposure, whether physiological or pharmacological.
In addition, this subset may have phosphatase and tensin homologue mutations. Type II
endometrial cancers, however, are estrogen–independent, usually high grade, have a poor
prognosis, often diagnosed at later stages and are usually of papillary serous, clear cell, or even
high-grade endometrioid pathology. Type II cancers may have a link with P53 tumor sup‐
pression mutation and the endometrial milieu of Type II cancers is often associated with polyps
or simply atrophic in nature.
At diagnosis, the malignancy is frequently found to be localized or within the borders of the
uterine corpus in 72-75% of instances, especially since they present early with abnormal uterine
bleeding.[11, 15] As mentioned earlier, the chance that postmenopausal bleeding is a result of
cancer substantially escalates with a woman’s age. Endometrial cancer is usually diagnosed
in early stages, although up to 20% of patients with clinical stage I may have indications of
extrauterine spread at time of surgical intervention.[22] The relative estimated survival rates
at the 5- and 10-year mark are approximately 82% and 79%, respectively.[2]
2. Surgical management
Although not the focus of this chapter, initial evaluation and workup is usually achieved via
endometrial biopsy and ultrasound. Abnormal uterine bleeding is often the most common
presentation that is seen. Current recommendations from the American College of Obstetri‐
cians and Gynecologists and other governing bodies still recommend the evaluation of all
patients with postmenopausal bleeding for likelihood of endometrial cancer. In addition, any
female over the age of 40 years with abnormal bleeding should also be evaluated. This
evaluation consists of obtaining tissue either by an endometrial biopsy or dilatation and
curettage.
After histologically confirmed diagnosis, additional evaluation to rule out metastasis may be
considered. A chest radiograph may be helpful to note any simultaneous pulmonary disease
or involvement and to rule out possible metastases to the lung.[13] In some cases, the meas‐
urement of CA-125 is also obtained because in some women with advanced stage disease at
time of diagnosis, CA-125 usually may be elevated. These elevated levels can help in deter‐
mining adequate response to treatment or recurrence of disease during post–treatment
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surveillance.[23-24] However, for the typical histology of Type I, endometrioid Grade 1 and
clinical stage 1 patient, a physical examination and chest X-ray is usually only required.
In the majority of cases, the subsequent step involves surgery for definitive treatment, staging
to determine the extent of the disease, and to reduce tumor burden in advanced stages with
extrauterine disease. In 1971, the International Federation of Gynecology and Obstetrics (FIGO)
put forth a comprehensive clinical staging system, which was used worldwide.[25] This initial
step helped to standardize to some degree the diagnosing and relevant treatment of the disease.
However, since 1988, clinical staging has mainly been replaced by surgical staging especially
since it does not fully evaluate significant histopathological features. [22, 76-78] The Gynecolog‐
ic Oncology Group (GOG) carried out two large–scale prospective trials looking at surgical
staging in 1984 and 1987.[22, 26] The results from these studies aided in determining the
important prognostic factors along with indicated treatment goal. Along with age, race, and
endocrine status, it was shown that prognosis is related to the presence or absence of certain
uterine and extrauterine risk factors. Uterine factors include histologic type, grade, depth of
invasion into the myometrium, isthmus-cervix extension, and lymphovascular space inva‐
sion. Extrauterine factors include adnexal metastasis, intraperitoneal spread, positive perito‐
neal cytology, pelvic and aortic node metastasis, and estrogen/progesterone receptor activity.
[27] FIGO stage is often considered to be the single strongest predictor regarding outcome in
endometrial cancer based on results from various multivariate analyses.[28]
Current staging is based on the FIGO 2009 staging criteria.[25-26, 29-31] The procedure of
surgical staging includes an adequate evaluation of the peritoneal contents, peritoneal
cytologic washings, hysterectomy, bilateral salpingo-oophorectomy, cytoreduction of all
visible disease, and bilateral pelvic and para-aortic lymph node dissection.[11, 13] Ideally, the
procedure should entail the same components whether done via a laparotomy or by minimally
invasive surgery (MIS). In the instance where a patient is unable to undergo surgery, whole
pelvic and intracavitary radiation may be used as definitive treatment. However, some data
have shown a notable decrease in 5-year survival times for clinical stage 1 disease treated in
this maner (67%) compared to surgery alone (87%).[11]
3. History of laparoscopy in management and staging of endometrial cancer
The introduction and involvement of laparoscopy has become truly integral and beneficial in
management of endometrial cancer. For more than 30 years, gynecologic surgeons have used
laparoscopy for many procedures, including oophorectomies, ovarian cystectomies, and
bilateral tubal ligations. Earlier research studies published information on both the feasibility
and technique of radical hysterectomy with pelvic and para-aortic lymphadenectomy.[32-35]
These helped set the foundation for the possibility of full and comprehensive surgical staging
using an MIS approach. Of note, laparoscopic intervention would not get its introduction into
the field of gynecologic endometrial cancer until the earlier part of the 1990s. A 1992 publication
by Childers et al.[36] was the first to report on laparoscopically–assisted vaginal hysterectomy
(LAVH) for management of endometrial cancer based on two cases. The case report also
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mentioned techniques such as port placement, insufflation methods, and lymphadenectomy
involving pelvic and para-aortic nodes. In a subsequent study series, Childers et al. published
data involving the first use of laparoscopy in surgical staging of endometrial cancer.[37] The
data showed a total of two conversions to laparotomy in their population (n= 59), with most
common indications being complications such as transected ureter and incidental cystotomy.
Interestingly, additional deductions from this study were that this new technique appeared to
have similar operating times to conventional laparotomy, however, with an increased degree
and length of learning curve for surgeons. Another study looked at the utility of LAVH and
laparoscopic lymph node dissection with supporting results of association of decreased
postoperative pain and blood loss with increased lymph node yield. Yet this study did show
increased operating time compared to open surgery.
Since the initial case reports and other similar retrospective studies done around that time, the
development and advancement of minimally invasive laparoscopic methodologies to the
surgical staging of endometrial cancer has continued. Later studies have included multiple
variables such as description of feasibility reports of the standard laparoscopic method,
outcome analysis of open surgical versus laparoscopic techniques, analysis of cost-effective‐
ness, and even development of laparoendoscopic single-site surgery (LESS).[37-46]
4. History of robotics in gynecologic surgery
The natural progression in medicine, and science and technology, tends to show that with new
research comes novel breakthroughs. This is evidenced in a wide variety of procedures,
algorithms, medications and in this case equipment. More often than not, these tend to be
helpful in the advancement of the art of medicine. This effect is seen directly with the estab‐
lishment of robotic surgery in the field of gynecologic surgery. We have clearly seen a
revolution in the armada of gynecological interventions with MIS over the last three decades.
[47] The field of robotic surgery has undergone rapid advancement, especially in gynecology,
[7-8], since it was originally developed for medical and surgical use in battle zones. The goal
was that robotic surgery could be used by surgeons in a remote location to perform simple or
complex procedures with similar skill, technique and outcomes as if done in a regular
operating room.
There are earlier models that helped to pave the way for the advanced systems currently in
use and lead to development in the field and technique. One such model and the first robot to
assist in a surgery was a single robotic arm known as Automated Endoscopic System for
Optimal Positioning (AESOP) developed by Computer Motion Inc. (Computer Motion, Inc.,
Santa Barbara, CA, USA).[48-49] Cleared by the Food and Drug Administration (FDA) in 1994,
this device was made to hold and manipulate an endoscope and remove the need for an
assistant. In addition, it was designed to give a surgeon improved control over visualization
and also allow command over the laparoscope using voice-activation.[50] The first commer‐
cially available robotic system, ROBODOC, described in 1992 was a robotic arm designed for
use in orthopedic hip prosthesis surgery[49], and allowed for accurate incisions in the femur
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bone for implant insertion. In 1998, Computer Motion Inc., marketed another model that had
been in development called ZEUS Surgical System (ZSS), which had a 2-D imaging system and
robotic arms made to mimic the surgeon’s arms. Two arms were added to the AESOP to create
the ZEUS. The arms also allowed for downscaling of movement from the surgeon’s hands and
elimination of tremors. The surgeon sat at a console, which helped to decrease fatigue
especially in longer operations and expanded on the possibility of telesurgery or remote
location surgery.
Figure 1. Da Vinci Surgical System with additional training console
Another company, Intuitive Surgical, Inc. (Intuitive Surgical, Mountain View, CA, USA) also
developed a robotic surgery assist model called the Da Vinci Surgical System (DVSS) shown
in Image 1.[91] Unlike the ZSS, the DVSS used a 3–D vision system produced from two
endoscopes, which results in a perceptual 3–D image. It also was designed with the EndoWrist
system, which offered seven degrees of freedom. This resulted in the recreation of the dexterity
and range of motion of a surgeon’s hand, therefore allowing a high degree of accuracy and
flexibility. Instruments could thus also be rotated a full 3600.[51] The first successful surgery
was done in 1997 in Belgium.[52] The DVSS was eventually cleared by the FDA in 2005 for use
in gynecologic procedures and has full regulatory clearance with the coveted Conformité
Européenne (CE) mark in Europe.[53]
5. Advantages of robotic surgery
Even with the initially high cost of acquisition (estimated between 1– and 2 million U.S.
dollars) of a DVSS for an institution, there are many advantages of robotic surgery that
make it worthwhile. More than 7,000 peer–reviewed publications have been published on
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computer–enhanced robotic surgery. For example, the amount of clinical evidence and data
on the robotic surgery system and technique is increasing at a rate of 100 publications per
month on average.[54]
5.1. Dexterity
The invention of the ergonomic wrist instruments allowed for more accurate replication of the
movement at the wrist, including rotation.
5.2. Precision
The robotic surgical system provides the ability to improve the precision with which the
surgical procedure is carried out. This is due in part to different factors such as the EndoWrist
concept, tremor reduction (explained below), and improved field of view.
5.3. Field and depth of view
The ability to see in a 3–D image as mentioned earlier is truly a remarkable feature. As an old
adage of excellent surgical techniques, the need for adequate exposure and visualization is
vital. This is also one improved quality over the laparoscopic technique, which has a limited
2–D view. In addition, robotic surgery does have the benefit of greatly increased magnification
which adds ability for more precise fine microsurgery techniques. The robotic setup that
includes a viewing station for the assistants and other staff in the room provides both a great
interactive learning and teaching viewing option unique to this system.
5.4. Control and motion dampening
This technology was also seen in the earlier Zeus system. It gives the ability to reduce the
tremors created naturally by the extension of the fingers or the resultant tension due to fatigue
as operating times increase. This is somewhat similar to being on a cruise ship and not feeling
the rocking of huge waves but just that gentle back and forth enough to give the calm feeling
of being at sea. However, the robot is able to filter out unnecessary hand and finger motions
which results in safer, more accurate intracorporeal movements.
5.5. Decreased blood loss
This can be seen as a direct result of the factors above, especially greater instrument control,
viewing ability, and small entry sites.
5.6. Learning curve
Studies have looked at the required learning to be proficient in both laparoscopic and robotic
techniques, with the latter often noted to be less difficult to acquire. This is due to the ergonomic
setup and more counter-intuitive hand movements needed compared to a laparoscopic style.
It is suggested that 20 robotic procedures are needed for proficiency.[55-56] Operative times
tend to decrease and the nodal counts increase with increased surgeon’s experience.
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5.7. Decreased surgeon fatigue
The surgeon operator console provided on the robotic surgical system is a great enhancement,
especially in longer operations. [57]
6. Techniques of robotic surgery
The use of port sites and the selection of these ports are important in MIS. As mentioned earlier,
the actual technique of staging should ideally be the same regardless of type of abdominal
incision.
Figure 2. Schematic demonstration of the port placement in robotic assisted operation for endometrial carcinoma
Techniques include either single-site port or multiple port use and other factors play a role in
determining which the best approach is used.
Figure 3. Pelvic lymph node retrieval
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Our patients undergo a bowel prep regimen. Patients are positioned securely on a foam
memory pad with Velcro straps placed across the breasts. This is critical for the 290 Trende‐
lenburg position for the entire case. Patients are placed in lithotomy in Allen stirrups. A uterine
manipulator is used in the majority of cases. Typically, 5 ports are placed as shown in the
diagram, Figure 1.[58] The camera is placed approximately 25 cm above the pubic symphysis.
The robot is then docked from the patient’s left side. A 00 scope is used. The fenestrated bipolar
and the monopolar hot shears are used as the operating instruments.
Figure 4. Para-aortic lymph node retrieval.
During indicated lymphadenectomy, pelvic and/or para–aortic, adequate dissection is
essential. The robotically assisted system and technique help with improving node yield. The
following images shown are during lymph node harvesting for both the pelvic and the para-
aortic lymph nodes during cases at our institution. Image 2 shows the intraoperative dissection
and removal of nodes in the pelvic cavity, while Image 3 shows the dissection and removal of
para-aortic nodes. In Image 3, the aorta is seen on the left of the image (top-down view)
branching into the right and left common iliac arteries.
7. Comparison of outcomes between open surgery and MIS
Total laparoscopic hysterectomy was compared to total abdominal hysterectomy in the LACE
trial.[59] In this trial, there was notable improvement in quality of life for up to 6 months for
the participants. Also, on that trial, there were more frequent serious adverse outcomes in the
laparotomy versus the laparoscopy group.
The largest randomized prospective multicenter study to evaluate outcomes between open
surgery and MIS is known as the Gynecologic Oncology Group (GOG) LAP2 trial, a 10-year
data accrual study.[60] It compares outcomes between incidence of surgical complications,
perioperative morbidity and mortality in stage I or IIa, grades I to III endometrial/uterine
cancer in patients being staged with either traditional laparotomy approach versus compre‐
hensive laparoscopic staging. The GOG in this trial aimed to evaluate the feasible role of a
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laparoscopic method in the primary surgical treatment of endometrial cancer in terms of
staging rates, safety, recurrence, and survival. In that study, the rate of conversion to open
surgery was 26%. The reasons for conversion were poor visualization, extrauterine spread and
bleeding. It was noted that as the BMI increased, so did the rate of conversion. With a BMI of
less than 20, the success rate was 90% compared to 34% with a BMI of 50. The median number
of lymph nodes harvested was not significantly different. The complications were also
evaluated. In the LAP2 study, the hospital time was 2 days in laparoscopic group compared
to 4 days in the laparotomy group. The oncologic outcomes of the comparison were reassuring.
The estimated 5–year survival rate was 11.6% and 13.7% for laparoscopy and laparotomy,
respectively. The overall survival rate was essentially equivalent between the two groups at
89.8% at 5 years.
There have been many retrospective and other studies comparing outcomes and complications
between laparotomy and robotic/laparoscopic surgery.[79-81] The key differences between the
two are outlined below.
7.1. Estimated blood loss
The use of smaller multiple incisions compared to a larger incision portends to an expected
decreased blood loss. In addition, the magnification and ability to control small blood vessels
contributes significantly to the decreased blood loss noted. In a study by Gaia et al. comparing
outcomes in laparotomy versus laparoscopic techniques, outcomes were similar except for a
statistically significant reduction in blood loss favoring the laparoscopy group. However, there
was no difference in transfusion rates.[61] In other studies, however, robotic surgery was
associated with reduced blood loss and transfusion when compared to conventional laparo‐
scopy.[53]
7.2. Length of operating time
Operating time has been shown in studies to be shorter in open surgery compared to MIS.
Some studies suggest that operating time was on average 30 min longer for laparoscopic
procedures.[59] In the LAP2 trial, operative was longer for laparoscopy by about a median of
70 min.[60] To some degree, this also is based on surgeon expertise with MIS and potential
limitations with instrumentation. Some of these limitations are overcome by the robotic
platform.
7.3. Increased exposure/visualization
Laparotomy may seem to have increased exposure simply due to the large abdominal incision
created during the procedure. However, with the magnification obtained during laparoscopy
visualization is superior, especially in the deep pelvis.
7.4. Length of Hospital Stay (LOHS)
Due to smaller incisions with minimally invasive techniques, faster expected healing and
recovery time are seen in MIS compared to open surgery. This results in decreased need
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for prolonged admission after operation. As an example, in the LAP2 trial, hospital time
was shorter, 2 days with laparoscopy compared to 4 days with laparotomy.[60] He et al.
[62] in a meta–analysis noted shorter length of hospital stay (mean difference [MD], -3.42;
95%  confidence  interval  [CI],  -3.81  to  -3.03;  p  <  0.01)  with  laparoscopy  compared  to
laparotomy.  Other  studies  have  also  demonstrated  similar  results  regarding  decreased
LOHS with laparoscopy.[60, 63-65]
7.5. Lymph node yield
Various  studies  including  the  previously  mentioned  GOG  LAP2  trial  have  focused  on
lymph node yield in either approach. Some studies have shown a similar amount of nodes
sampled or retrieved while others have shown increased on either side. Also, in the 2013
meta–analysis  of  nine  randomized  controlled  trials  by  He  et  al.,  the  data  showed  no
statistically significant difference between either approach pelvic node yield (MD, 0.45; 95%
CI, -0.41 to 1.32; p = 0.30).[62]
7.6. Complications
In the GOG LAP2 trial, which remains the largest prospective randomized trial comparing
laparoscopy to laparotomy in the management of endometrial cancer, the combined compli‐
cation rate inclusive of vascular, urinary, bowel, and nerve was higher in the laparoscopy
patients (10%) in comparison to the laparotomy group (8%).[60] DeNardis et al. have however
shown reduced complications in robotic cohorts. In that study, major peri–operative compli‐
cation was found to be 3.6% in the robotically-assisted cohort compared to 20.8% in the
laparotomy group.[66]
8. Comparison of robotic surgery versus conventional laparoscopy in
endometrial cancer
These two techniques are both types of MIS, although one can often think of robotic surgery
as being the younger, more advanced sibling. In this way, robotic surgery in many ways has
helped to enhance the techniques and outcomes involved in laparoscopic surgery. Two areas
of note where this unique edge is definitely appreciated is in the treatment of both the elderly
and the obese with endometrial cancer. These two conditions require additional concern due
to possibility of co–morbidities, access, and post–operative survival and outcomes. Cho and
Nezhat in their review of 754 case identified complication rates of 10.5%, 12.2%, and 44.6% in
robotic hysterectomy, laparoscopic hysterectomy, and abdominal hysterectomy, respectively.
[67] In the open cohort, the majority of complications were related to wound infections and
bowel dysmotility. There was also a lower rate of conversion in the robotic group when
compared to the laparoscopic group. The above–mentioned advancement in the robotic system
is no doubt responsible for this observation.
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8.1. Decreased Estimated Blood Loss (EBL)
Decreased blood loss is seen in many studies comparing the two techniques with robotic being
associated the lesser amount. In Seamon’s study, estimated blood loss was 100 and 250 mL,
respectively, for robotic versus conventional laparoscopy.[68]
8.2. Decreased Length of Hospital Stays (LOHS)
Especially in the current medical climate with current societal economic situations, the trend
is to improve the proper utilization of resources while, at the same time, decreasing costs
wherever possible. Although robotic surgery comes with a substantial investment cost, having
shorter hospital admissions especially postoperatively can help to reduce operating costs from
a different angle. Studies have shown either similar in some cases or usually a slightly
decreased LOHS in robotic surgery.[68]
8.3. Decreased Operating Room (OR) time
This is related to surgeon skill, experience and expertise. Since robotic surgery has been shown
to have an improved learning curve, this may play a role in overall operating time. Also,
coupled with the other benefits robotic surgery offers, this may result in faster times from
incision to incision or from docking to incision in some studies. However, some studies have
shown similar operating times between the two methods. Seamon et al. in their comparison
of robotic to conventional laparoscopy reported reduced mean operative times in the robot
group, 242 versus 287 min.[68]
8.4. Decreased chance of conversion to laparotomy
Some studies, both observational and retrospective comparison, have noted less chance for
conversion with decreased visualization, body habitus, patient weight, and comorbidities
often being reasons cited for having to do so. This occurs less in robotic than laparoscopic
surgery. Gaia et al. demonstrated a 9.9% conversion rate in laparoscopy compared to 4.9% for
the robotic approach.[61]
8.5. Patients with increased BMI
The prevalence of obesity is increasing. Obesity is associated with increased surgical morbid‐
ity. There is an associated increase in blood loss, operative times, wound complications, and
venous thromboembolism. Hence, the development of newer techniques that will provide a
comparable surgical staging with reduced morbidities is very attractive. The obesity factor
affects both techniques but the qualities of the robotic surgery tend to lend toward decreased
morbidity compared to laparoscopic surgery. Recall in the LAP2 trial that the success of
surgical staging was decreased with increasing BMI. The robot seems to overcome this
limitation associated with conventional laparoscopy. In a retrospective study by Gehrig,[69]
complete surgical staging was accomplished in 92% of robotic patients in contrast to 84% in
the laparoscopic group. Also notable was the shorter operative times (189 vs 215 min, p = 0.004,
less blood loss (50 v 150 mL, p < 0.001) and a statistically significantly shorter hospital stay.
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Another retrospective study done by Mendivil et al. comparing robotic, laparotomy, and
conventional laparoscopic cohorts of morbidly obese patients (BMI > 40 kg/m2) compared the
outcomes of each procedure.[82] Robotic surgery had the longest operating time compared to
laparoscopy and laparotomy (2.78 vs 1.82 and 1.35 h, p < 0.001) but had the least estimated
blood loss respectively (100 vs 175 and 250 mL, p = 0.002). The length of hospital stay was
significantly shorter with both minimally invasive methods compared to laparotomy (2 vs 4
days, p = 0.002)
8.6. Patients of advanced age
Elderly patients usually have more co–morbidities and are generally poorer surgical candi‐
dates with concomitant more advanced disease, which may require more surgical intervention.
There have been studies looking at the utility of robotic surgery in this scenario, as well as
laparoscopic surgeries. In a retrospective analysis by Scribner et al., laparoscopic staging was
completed in 77.6% of patients. The operative time was increased for the laparoscopic group,
however, there was no increased morbidity from longer anesthetic times.[70] Another study
by Lavoue et al.[87] compared a population (n = 113) of advanced age patients (greater than
or equal to 70 years) with endometrial cancer undergoing surgical staging by either robotic or
traditional open surgery. The robotic group had longer operating times (244 vs 217 min, p =
0.009) but less estimated mean EBL (75 vs 334 mL, p < 0.0001), less minor adverse events (17
vs 60%, p < 0.001) and decreased mean LOHS (3 vs 6 days, p < 0.0001). However, no statistical
difference (p = 0.61) was noted in the 2-year disease–free survival during follow-up.
A single institution retrospective chart review looked at the safety of robotic surgery in a cohort
of patients with endometrial cancer (n = 228) compared to laparotomy.[88] The cohort was
subdivided by method of surgery (robotic vs laparotomy) and age (<65 vs 65 years and older).
Older patients undergoing robotic surgery had decreased estimated blood loss (131 vs 235 mL,
p = 0.03), decreased rate of postoperative ileus (0 vs 15%, p = 0.04), decreased perioperative
surgical complication rate (4 vs 30%, p = 0.01), and decreased LOHS (2.2 vs 4.4 days, p < 0.01)
compared with laparotomy. The rate of discharge home was similar with compared to
laparotomy (96 vs 91%, p = 0.45).
Robotic surgery with the associated advantages such as decreased EBL, decreased LOHS, and
potentially decreased postoperative morbidity may show potential for improved outcomes
compared to laparoscopic surgery and laparotomy. Further studies may be needed to evaluate
this comparison.
8.7. Single-Port Access (SPA)
The progression from traditional open surgery toward minimally invasive methods, both
robotic and conventional laparoscopic, has resulted in further innovation such as attempts at
using fewer port entry sites, less trocars, and smaller abdominal incisions.
Laparoendoscopic single–site surgery (LESS), a novel technique, may lead to an additional
decrease in the overall invasiveness of conventional laparoscopy. Fanfani et al.[83] in a 2012
publication of a single institution cohort trial looked at laparoendoscopic single–site surgery
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(LESS) in surgical management of early–stage endometrial cancer. The results showed median
age of 57 years (42–68), median BMI of 24 kg/m2 (21–30) with median operating time of 105
min, and median EBL of 20 mL (10–180). The skin and fascial incision needed for this single-
port access approach was 2.5 cm (median 2.2 cm, range of 2.0–2.5) with all patients reported
being satisfied with both pain control postoperatively and the cosmetic results.
Some difficulties inherent with LESS include instrument crowding as well as clashing,
decreased and/or poor visualization, loss of triangulation, and ergonomic issues.[85] The
combination of robotic surgery with LESS may help to overcome some of the technical
limitations noted with LESS. A retrospective case–control study by Fagotti et al. looked at the
comparison outcomes between robotic and laparoendoscopic single–site hysterectomy for
treatment of early endometrial cancer.[86] Although the median OR time was less in the robotic
versus laparoendoscopic group (90 min vs 107 min), the data did not produce any seemingly
clinically relevant differences.
Figure 5. Single site port system
The robotic single–site port system[89] which enables operating through a small umbilical
incision in common procedures such as benign hysterectomies, cholecystectomies, or salpin‐
go–oopherectomies. The recommended size of incision needed for this five–lumen port (see
Image 4[93]) is typically about 1.5 cm. As seen the port has five channels. There is a channel
for the 8.5 mm scope, two robotic arms, a surgical assistant port, and an insufflation port. The
instruments are semiflexible and capable of triangulation. Currently, the instruments lack the
EndoWrist articulation, which might be disadvantageous. The advantages of this technique
include the promise of potentially virtually scarless surgery due to the small incision, in
addition to the known ones of robotic surgery such as decreased EBL and LOHS.[90] More
prospective studies with larger numbers are needed to compare robotic single–site surgery
with standard robotic multi-site surgery for procedures commonly done.
A pilot study published in 2013 by Vizza et al.[88] looked at the feasibility and safety of using
robotic single-site hysterectomy in patients with low–risk early stage endometrial cancer. The
five–lumen port described above was used with the size of the umbilical incision ranging from
2 to 2.5 cm. The median age was 64 years with a median BMI of 26.6 kg/m2. The results showed
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median OR time to be 90 min, median blood loss of 75 mL with no reported conversion to
laparoscopy or laparotomy, and median LOHS of 2 days. No reported complications occurred
neither intra– nor postoperatively. The study concluded that robotic single–site hysterectomy
was a safe and technically possible option in this patient group. Future studies with other
gynecologic oncologic procedures and cases need to be carried out to evaluate the feasibility
and advantages of this technique.
8.8. Cost
Any cost analysis of the different modalities of surgery and staging in endometrial cancer
cannot overlook the impact of hospital stay on overall cost. Since the robot has been effective
in shifting hysterectomy and staging to an essentially an outpatient procedure, there will be
an anticipated decrease in overall hospital cost.
A cost effective analysis of robotically assisted management of new endometrial cancer was
performed by Leitao et al.[71] The costs were inclusive of all surgical aspects of care provided
up to 6 months following discharge. In that study, the total mean amortized cost per case was
$20,487 for laparoscopy, 20,467 for robotically assisted, and $24, 642 for laparotomy. It was
concluded that when laparotomy rates are reduced by virtue of the robot, then there is notable
cost neutralization. A similar finding of laparoscopy being the least expensive approach was
noted. Interestingly, if the cost of the robotic disposable instruments did not exceed $1,046,
then from a societal perspective the robotic approach would be the least expensive.[46] In other
studies, the utilization of the robot was deemed to be approximately 1.5 times higher than
conventional laparoscopy. However, the mentioned reduction in completion of case and
decreased conversion to laparotomy cannot be ignored.
Future studies will probably examine the use of the robot in debulking advanced cases of
uterine cancers. Single–site surgeries will probably become more popular. Advancements in
the actual technology are only expected to sky rocket. One can only imagine what the next step
involves or what direction robotic computer-enhanced telesurgery would take. The important
factor overall is being able to find that balance of effective patient care and management with
the proper utilization of resources based on overall cost as well as reimbursement.
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